Member Info for Moneymunch

Friday 04 May, 2018 Microsaic Systems AGM Statement RNS Number : 0149N Microsaic Systems plc 04 May 2018 4 May 2018 Microsaic Systems plc ("Microsaic", "Microsaic Systems" or the "Company") AGM Statement Microsaic Systems plc (AIM: MSYS) will hold its AGM today, at 11 am, at the offices of Nplus1 Singer Advisory LLP, One Bartholomew Lane, London, EC2N 2AX, where the Company's Chairman, Peter Grant, will make the following statement: "The Board is pleased to report encouraging progress with the Company's commercial development since the announcement of the 2017 results on 5 March 2018. The collaboration with one of the foremost players in the global market for scientific instrumentation is progressing in line with the Board's expectations in the technical integration phase of a bioprocessing application. As previously announced, two new OEM agreements have been signed in the Company's traditional small molecule markets. On 28 March, the Company announced an agreement with Unimicro Technologies Inc. ("Unimicro"), for the integration of its compact 4500 MiD� mass spectrometry ("MS") detector with Unimicro's Capillary Electrophoresis platform. Once integrated, the combined product will be sold by Unimicro in China via its extensive distribution network. In April, Microsaic signed an agreement with Knauer Wissenschaftliche Ger�te GmbH ("Knauer"), for the integration of Microsaic's compact 4500 MiD�MS technology into Knauer's liquid chromatography platform, and for the combined product to be sold direct by Knauer in Germany and globally via its extensive distribution network. Orders received in the year to date are from a wider customer base than last year and in total cover the same number of instruments as delivered for the whole of 2017. The Board remains confident in the longer-term prospects for the business."

Glenn Tracey, CEO of Microsaic Systems. �With over 60 patents to date, we�re committed to further developing miniaturised mass spectrometry to bring the benefits of robust point-of-need analysis to biologics detection. A range of biological entities, such as monoclonal antibodies, can now be analysed by our technology in just minutes. This has a significant and very positive impact on biologic manufacturing productivity, and we are working with some of the foremost companies in the field.�

as we approach Friday's AGM....the BoD must be very pleased with progress made and more than confident of a successful conclusion with their global biopharma partner as H2 2018 fast approaches, and will be in their company at the American Society of Mass Spectrometry in 4 weeks time... ...Gla holders....more good news could drop at anytime....On and Up!!!:-)

Yep, exciting times , Microsaic all looks set for some stellar upside imho, and i wouldn't be surprised if more good news comes early this week in time for Friday's AGM. Gla ;-)

All the key players will be there, which presumably includes Microsaic's global biopharma partner, one of the foremost players in the global market for scientific instrumentation......Tick Tock....Gla Holders ;-) Microsaic ‏ @Microsaic Apr 15 We will be exhibiting at ASMS in June, San Diego. Come and meet us: booth #1005 American Society for Mass Spectrometry 66th Conference on Mass Spectrometry and Allied Topics June 3 - 7, 2018 | San Diego, CA The American Society for Mass Spectrometry (ASMS) was formed in 1969 to promote and disseminate knowledge of mass spectrometry and allied topics. ASMS is a non-profit 501 c 3 corporation. Membership includes over 8,500 scientists involved in research and development. Members come from academic, industrial and governmental laboratories. Their interests include advancement of techniques and instrumentation in mass spectrometry, as well as fundamental research in chemistry, geology, forensics, biological sciences and physics. https://www.asms.org/conferences/annual-conference/exhibitors/exhibitors-corporate-members-2017

Cheers all, undoubted transformational multi-bag potential and prospects, which appear to be well under the investor and market radar at the moment .....sooner or later Microsaic will be in full focus and firmly in the spotlight imho....Tick Tock...Gl ;-)

Key commercial goals for 2018 Over the coming 12 months, we are aiming to significantly advance our commercial development in the biopharma market, as well as continuing to support existing partners and establish new partnerships with OEMs which see the potential of our unique technology. The primary focus will remain on bioprocessing and successfully completing phase two of our agreement with one of the foremost players in the global market for scientific instrumentation. Our platform approach to development, and its commercialisation through incremental product releases, is relatively low risk and designed to ensure that our technology remains distinct and increasingly suited to the evolving needs of pharmaceutical R&D and manufacturing. We are looking to leverage this capability to open up new opportunities for future growth.

Chairman's Statement April 2018 - Peter Grant ex CEO of Skyepharma, instrumental in their meteoric rise in fortunes and subsequent �440m merger. Gla ;-) Investment case Having joined as Non-Executive Chairman at the beginning of January 2018, in my first statement, I thought it would be informative to set out what attracted me to join Microsaic: � There is a clear vision and strategy, which recently appointed Chief Executive Officer (�CEO�), Glenn Tracey, and a skilled management team and staff have the commitment and expertise to deliver; � A key target is the growing and very substantial market for manufacturing biopharmaceuticals (�bioprocessing�), where the Company�s products have the potential to support significant enhancements in efficiency and quality assurance; � The primary approach to market is through strategic collaborations with OEMs (�Original Equipment Manufacturers�). In December 2017, one collaboration, with one of the foremost players in the global market for scientific instrumentation, was extended into a second phase of integration, ahead of a potential commercialisation phase; and � The Company�s technology, originally conceived at Imperial College London, is protected by over 60 patents, many years of in-field experience, and a pragmatic development programme focused on meeting unmet market needs and creating new market opportunities.

Cheers, all bodes well and highly encouraging that miniaturisation is highlighted as a prominent factor in fuelling the growth in MS....and so Microsaic couldn't be better placed imho and sooner or later this current rockbottom bargain low sp will be a distant memory....more good news very likely, transformational news in the pipeline. Gl :-)

PHARMACEUTICAL Clinical Mass Spectrometry Market to receive overwhelming hike in Revenues by 2019 April 26, 2018 ........... Technological advancements leading to new product launch is a prominent factor fueling growth of the clinical mass spectrometry market Advancements in technology includes miniaturization of mass spectrometry instruments  and increasing automation of the entire spectrometric unit to reduce human efforts and improve efficiency of the instruments. The fully automated analyzer launched by Thermo Fisher in June 2017, is a step closer to achieve entirely automated systems in the mass spectrometry market that can be customized easily to be compatible with the laboratory information systems. http://www.coherentchronicle.com/clinical-mass-spectrometry-market-to-receive-overwhelming-hike-in-revenues-by-2019/

That's about it Albinio74, sales revenues are the bottom line and the more commercial agreements, especially with any of the key players with their global reach , will be highly significant and a major commercial opportunity for sales revenues to increase. The last couple of years have seen sales revenues decrease in Microsaic's traditional markets and a decline in Microsaic's fortunes, sp and market cap, hence the new business plan to focus on the lucrative market bioprocessing....new technology produced by Microsaic or any other competitor for that matter takes time for systems integration into their customers product and equipment and also takes time for validation by their partner's and their partners end-users etc...and Microsaic are well ahead of the curve imho Gl :-)

It's a multi-billion dollar market which is driven by a few select key multi-billion dollar companies and so smaller companies find it difficult to compete....and many smaller companies with cutting edge technology are quite often taken over and merged or grow by commercial agreements with the key players which is Microsaic's business plan.....Microsaic's miniaturised technology is definitely cutting edge and well advanced and are leaders in their field after years of development, and protected by over 60 patents. Last year they shifted their focus from small molecule detection to the lucrative bioprocessing market, which is expected to see massive growth and where mass spectrometry will play an important role, and where the benefits of miniaturisation will become highly relevant in reducing costs and making the equipment user friendly etc...the recent deals suggest that their latest technology has been well received and no doubt more commercial agreements will follow which could add significant value....but near term , it's news on the technology trials with their global biopharma partner that the market is awaiting....a game changer and instant multi-bag on disclosure of anyone of the following imho Gl :-) Key vendors • Agilent Technologies • Bruker • Danaher • PerkinElmer • Shimadzu Corporation • Thermo Fisher Scientific

Microsaic's CEO "As I've mentioned to you before, we are very pleased to say that progress is being made with one of the foremost companies in scientific instrumentation in bioprocessing. and in December, we completed a technical feasibility stage, we took the project forward into the technical integration phase." In the short term, our technology is going to be integrated with a wide range of techniques, it's probably worth mentioning some of those, particularly in terms of chromatography. That is preparative flash chromatography, liquid chromatography and also think layer chromatography but also in capillary electrophoresis and we're particularly interested in online reaction monitoring. All those techniques are becoming increasingly popular to hyphenate with mass spec especially as target compounds are becoming more complex and by that, I mean targets such as peptides, small proteins, lipids and indeed a range of many other metabolites. This is going to be done through partnerships across many geographies; Europe, North America and Asia, and that's both through OEM's and also through value-added distributors who don't currently have mass spectrometry as part of their offering and want to partner with someone to offer seamless integration with mass spec.

"a flexible chip format and can be integrated with existing products for a seamless workflow".......sounds familiar???.... An instant multi-bag if Thermo Fisher was confirmed as Microsaic's global bio pharma partner. Gla ;-) Thermo Fisher Scientific Reports 23 Percent Revenue Growth in Q1 Apr 25, 2018 | staff reporter This article has been updated with additional information from Thermo Fisher Scientific's earnings call. NEW YORK (GenomeWeb) � Thermo Fisher Scientific today reported 23 percent growth in revenues for the first quarter, driven by strong results across all of its business segments. "We achieved excellent growth in revenue and earnings," said President and CEO Marc Casper during a conference call this morning to discuss the company's financial results. "Our team executed well to capitalize on the good market conditions, and we continued to successfully execute our growth strategy. ... Our great performance in Q1 sets us up to deliver another outstanding year." Thermo Fisher reported $5.85 billion in total revenues for the first quarter, up 23 percent from $4.77 billion during the same period last year. Revenues beat expectations by Wall Street analysts of $5.63 billion. Organic revenue grew 7 percent, acquisitions contributed 12 percent to revenue growth, and currency effects increased revenue by 4 percent. ......... Finally, laboratory products and services revenue, which include the Patheon business that Thermo Fisher acquired last August, grew 42 percent to $2.41 billion compared to $1.70 billion in Q1 of 2017. This segment, which grew 6 percent organically, saw strong growth in its clinical trial logistics and research channel businesses. During the call, Casper pointed out that recent products contributed to the revenue growth, among them the Thermo Scientific Orbitrap Q Exactive HF mass spectrometer. He also noted several new product launches, for example, the Ion GeneStudio S5 series of next-generation sequencers, which he said feature a flexible chip format and can be integrated with existing products for a seamless workflow. He also mentioned the company's expanding Oncomine portfolio of liquid biopsy and immuno-oncology assays that help researcher bring new cancer diagnostics to the clinic. https://www.genomeweb.com/business-news/thermo-fisher-scientific-reports-23-percent-revenue-growth-q1#.WuF0eZch3IU

Microsaic @Microsaic � Feb 1 Our Mass Detector integrates seamlessly with your chromatography, as seen here with #Gilson HPLC. With our technology, no large, noisy external roughing pumps are needed, no cumbersome exhaust is needed, and with low nitrogen and solvent consumption! Truly compact #massspec http://www.gilson.com/en/AboutGilson/GilsonMissionHistory.aspx#.WuFgQ5ch3IU Today, Gilson remains family owned, and manufactures purification systems, automated liquid handlers, pipettes (including the world-renowned PIPETMAN� brand of pipettes), fraction collectors, solid phase extraction (SPE) systems, detectors, injectors, and much more. From academia to industry, Gilson delivers high-quality, dependable solutions to researchers around the world. Since 1957, Gilson�s world headquarters has been located in Middleton, WI. Gilson has expanded and opened new Centers of Excellence to keep up with global demand. In 1963, Gilson opened a manufacturing facility, Gilson S.A.S. northeast of Paris in Villiers-le-Bel, France. In 2013, Pure Lab Plastics, a laboratory plastics manufacturer, joined the Gilson organization and in early 2017, another manufacturing facility opened in Vannes, France, Gilson Purification, S.A.S. Gilson also has local sales and service teams that include a vast distribution network in countries throughout North and South America, Europe, Middle East, Africa, (EMEA) and Asia Pacific (APAC). http://www.gilson.com/Resources/VERITY_1900_MS_Detector_Users_Guide_LT309160_01.pdf Microsaic's product labelled as Gilson.

More commercial deals in the pipeline more than likely, and progress and fine detail on the recent deals would be most welcome....and news on the BIG one at anytime....the first phase of the collaboration with their global biopharma partner, the feasibility study, lasted 7 to 8 months from April 2017 until confirmation by Rns 13/12/17 that the collaboration agreement had been extended for product integration with their partner's equipment and for further validation by their partner's BIG pharma end users, and so we're already 5 plus months into this phase from the last update....Tick Tock Boom.....Gla holders;-)

Lol, yep, i was looking at TERN at 3p...Grrrrrrr........Microsaic's turn next with any luck. Gl ;-)

Lol, yep, i was looking at TERN at 3p...Grrrrrrr........Microsaic's turn next with any luck. Gl ;-)

Our TERN will come...Gla ;-)

New minaturised/micro product launches by Shimadzu UK....Colin Jump, Microsaic's previous CEO was MD at Shimadzu for 11 years before joining Microsaic and so maybe a connection to Microsaic's technology!!!??? Gla ;-) https://www.shimadzu.co.uk/